Taw qhia
Icatibant, zoo li pom nyob rau hauv lub npe hom Firazyr, tseem yog ib tug engineered peptide yooj yim ntawm bradykinin. Peptides, los ntawm kev txhais, yog luv luv ntawm cov amino acids koom nrog peptide daim ntawv cog lus, ib qho kev piav qhia uas haum rau Icatibant, koom nrog 10 amino corrosive buildups. Yeej, Icatibant zoo ib yam li C-terminal succession ntawm bradykinin, ib txwm tshwm sim peptide embroiled nyob rau hauv vasodilation thiab irritation.
Lub sub-atomic sib npaug ntawm Icatibant yog C59H89N19O13S, mirroring nws txoj cai ntawm carbon (C), hydrogen (H), nitrogen (N), oxygen (O), thiab sulfur (S) molecules. Nws cov qauv tsim muaj xws li lub voj voog pentapeptide txha nraub qaum dai kom zoo nkauj nrog cov chains sab thiab lub davhlau ya nyob twg kev sib sau ua ke. Qhov kev npaj tsis tsim nyog no ua rau Icatibant tshwj xeeb kos nrog bradykinin receptors, raws cov kab no tweaking bradykinin-interceded organic tshuaj.
Raws li peptide yooj yim ntawm bradykinin, Icatibant ua haujlwm los ntawm kev cuam tshuam txoj hauv kev uas sawv cev los ntawm bradykinin, tus tswv cuab hauv nruab nrab hauv cov voj voog xws li vasodilation, irritation, thiab torment sensation. Los ntawm emulating tus tsim thiab muaj peev xwm ntawm bradykinin, Icatibant tuaj yeem khi rau bradykinin receptors, chim siab rau cov dej num ntawm endogenous bradykinin. Qhov bar ntawm bradykinin receptors txwv qhov kev cuam tshuam qis ntawm bradykinin, muab cov txiaj ntsig zoo hauv cov xwm txheej uas tau piav qhia los ntawm kev ua phem bradykinin, xws li genetic angioedema (HAE).
Tsis tas li ntawd, lub cyclic pentapeptide spine ntawm Icatibant hloov kho nws lub suab thiab bioavailability, cov ntsiab lus tseem ceeb rau nws cov tshuaj muaj txiaj ntsig zoo. Qhov no atomic steadiness guarantees ncua ncua kev ua si, ua hauj lwm nrog txhawb kev hloov ntawm bradykinin-interceded tshua. Tsis tas li ntawd, kev xaiv ntawm Icatibant rau bradykinin receptors txwv tsis pub muaj kev cuam tshuam, txhim kho nws cov kev kho mob.
Hauv daim ntawv qhia,Icatibanttshwm sim raws li ib tug engineered peptide yooj yim nrog rau qhov zoo sib xws rau bradykinin, tau koob hmoov nrog lub peev xwm los sib npaug bradykinin-interceded organic tshua. Los ntawm nws cov kev sib txuas tshwj xeeb nrog bradykinin receptors, Icatibant siv cov txiaj ntsig zoo hauv cov xwm txheej uas tau piav qhia los ntawm kev ua haujlwm tsis zoo ntawm bradykinin. Nkag siab txog kev tsim atomic thiab cov khoom siv tshuaj ntawm Icatibant yog qhov tseem ceeb hauv kev ua kom nws lub peev xwm kho tau zoo rau kev tswj hwm ntawm cov kab mob sib txawv.
Ua li casIcatibantsiv nws cov tshuaj pharmacological?
Icatibantsiv nws cov tshuaj pharmacological los ntawm kev koom tes hauv kev hem thawj loj ntawm bradykinin B2 receptor, G protein-coupled receptor (GPCR) qhov tseem ceeb hauv kev tswj hwm vascular tone thiab porousness. Bradykinin, nto moo rau nws lub hwj chim raws li ib tug vasodilator thiab nruab nrab neeg ntawm irritation, ties rau lub B2 receptor, pib intracellular flagging fountains thiab ua rau physiological tshua.
Ua hauj lwm raws li ib tug bradykinin receptor phem txiv leej tub, Icatibant upsets kev sib txuas lus ntawm bradykinin thiab nws receptor, ntxhov siab vim receptor enactment thiab lub resulting flagging txoj kev. Yog li, qhov kev thov no cuam tshuam rau bradykinin-instigated vasodilation, vascular spillage, thiab lwm yam kev txhawb nqa ntawm provocative tshwm sim. Los ntawm nws cov yeeb yam tsis zoo ntawm B2 receptor, Icatibant muaj peev xwm txo qis cov kev mob tshwm sim cuam tshuam nrog cov xwm txheej sib cais los ntawm kev ua kom muaj zog bradykinin, xws li genetic angioedema (HAE).
Los ntawm kev cuam tshuam qhov kev txwv ntawm bradykinin rau nws cov receptors, Icatibant teeb tsa lub bar tiv thaiv kev cuam tshuam ntawm bradykinin, xyuas nws cov txiaj ntsig neurotic ntawm vascular muaj peev xwm thiab kev tawm tsam provocative. Cov tshuaj tiv thaiv no qhia txog nws txoj kev muaj peev xwm los daws qhov tsis muaj zog ntawm cov xwm txheej tau piav qhia los ntawm dysregulated bradykinin txav, raws li muab kev pab kho mob rau cov neeg cuam tshuam.
Dab tsi yog cov kev siv kho mob ntawmIcatibant?
Kev siv tshuaj kho mob tseem ceeb ntawm Icatibant yog nyob rau hauv kev tswj hwm ntawm kev ua phem ntawm kev muaj mob angioedema (HAE), ib qho teeb meem tsis tshua muaj tshwm sim tau piav qhia los ntawm qhov rov ua dua ntawm cov ntaub so ntswg loj thiab khaus. HAE yog coj los ntawm kev hloov pauv hauv C1 inhibitor zoo, ua rau tsis muaj kev tswj hwm ntawm txoj kev bradykinin thiab tsim tsis tsim nyog bradykinin.
Icatibant muaj kev pab ceev ceev ntawm HAE cov kev mob tshwm sim los ntawm kev cuam tshuam cov kev cuam tshuam ntawm bradykinin thiab ua kom tsis muaj zog ntxiv rau vascular spillage thiab cov ntaub so ntswg edema. Nws lub koom haum subcutaneous siv los txiav txim siab txog kev pabcuam tus kheej los ntawm cov neeg mob thaum pib ntawm kev quab yuam hnyav, ua rau kev ua haujlwm ntawm tus kheej txaus siab thiab txo qis kev siv kho mob.
Ib cag ntawm nws txoj haujlwm tau muab tso rau hauv kev saib xyuas HAE, Icatibant tau raug tshuaj xyuas rau cov ntawv thov ua tau nyob rau hauv ntau qhov xwm txheej cuam tshuam los ntawm txoj kev bradykinin. Cov qauv suav nrog angiotensin-hloov dua cov protein (Pro) inhibitor-instigated angioedema thiab genetic angioedema. Ob qhov kev kho mob ua ntej thiab kev siv tiag tiag tau nthuav tawm nws txoj kev tsim nyog thiab kev noj qab haus huv thoob plaws cov neeg mob sib txawv, nyob rau hauv txoj kev no nthuav dav nws txoj kev kho dua tshiab.
Kev kuaj mob hauv tsev kho mob tau khawb rau hauv nws qhov kev txaus siab dhau los HAE, tshwj xeeb tshaj yog nyob rau hauv kev mob angioedema tawm los ntawm Pro inhibitors. Cov lus teb tsis zoo no, cuam tshuam los ntawm kev sau bradykinin, nthuav tawm qhov kev sim hauv kev tswj hwm kev kho mob. Txawm li cas los xij, cov kev tshawb fawb qhia tias Icatibant tuaj yeem sib npaug qhov kev tawm tsam no, muab kev pab cuam rau tib neeg.
Tsis tas li ntawd, Icatibant qhov kev siv hluav taws xob nthuav tawm mus rau cov caj ces angioedema, ib qho teeb meem tsis tshua muaj tshwm sim tau piav qhia los ntawm qhov rov ua dua ntawm qhov loj ntawm ntau lub cev. Los ntawm kev tsom mus rau qhov tsis tsim nyog bradykinin txav zais qhov mob no, Icatibant muab kev kho mob tseem ceeb rau kev saib xyuas kev ua phem hnyav thiab ua haujlwm ntawm cov neeg mob kev txaus siab ntawm tus kheej.
Critically, kev ruaj ntseg profile ntawm Icatibant tau tob hauv paus los ntawm kev soj ntsuam dav dav. Nws siv thoob plaws cov neeg mob sib txawv, suav nrog cov neeg uas muaj cov kab mob sib kis los yog cov kab mob tsis meej, tau qhia txog kev ruaj ntseg thiab kev ncaj ncees.
Los ntawm thiab loj, cov ntaub ntawv pov thawj los ntawm cov chaw kho mob ua ntej thiab cov ntawv pov thawj pom zoo qhia txog kev hloov pauv thiab qhov txaus ntawmIcatibantnyob rau hauv tending rau bradykinin-intervened messes. Raws li cov chaw muab kev kho mob txuas ntxiv tshawb xyuas nws cov peev txheej pab tau thiab kho nws txoj kev siv, Icatibant tuav kev lees paub tias yog lub cuab yeej tseem ceeb hauv kev tswj hwm ntawm cov xwm txheej sib txawv uas tau piav qhia los ntawm txoj hauv kev dysregulated bradykinin.
Xaus
Hauv kev xaus,Icatibant, peptide muaj 10 amino acid residues, mimics bradykinin synthetically. Nws cov tshuaj cuam tshuam tau pom los ntawm kev sib tw antagonism ntawm bradykinin B2 receptor, zoo thwarting bradykinin-induced vasodilation thiab o. Tshaj li nws lub luag haujlwm tseem ceeb hauv kev tswj hwm HAE kev tawm tsam hnyav, Icatibant tuav cov lus cog tseg rau kev hais txog lwm yam kev mob tshwm sim los ntawm kev ua haujlwm bradykinin ntau dhau. Los ntawm kev nkag siab txog cov yam ntxwv ntawm molecular thiab pharmacological ntawm Icatibant, cov kws kho mob tuaj yeem kho nws cov kev tswj hwm zoo, yog li txhim kho cov txiaj ntsig kho mob rau cov neeg mob uas cuam tshuam nrog bradykinin-mediated disorders. Los ntawm qhov kev nkag siab tsis zoo no, cov kws kho mob tuaj yeem siv tag nrho lub peev xwm ntawm Icatibant kom txo tau lub nra ntawm bradykinin ntsig txog pathologies thiab txhim kho kev saib xyuas neeg mob.
Cov ntaub ntawv
1. Cicardi M, Banerji A, Bracho F, thiab al. Icatibant, tus tshiab bradykinin-receptor phem txiv neej, nyob rau hauv genetic angioedema. N Engl J Tshuaj. 2010; 363(6):{5}}.
2. Bas M, Greve J, Hoffmann TK. Pab tau txaus ntawm Icatibant nyob rau hauv angioedema actuated los ntawm angiotensin-hloov dua catalyst inhibitors: ib rooj plaub series. Ann Emerg Tshuaj. 2010; 56(3):{5}}.
3. Lumry WR, Li HH, Duty RJ, et al. Randomized fake kev kho mob tswj ua ntej ntawm bradykinin B2 receptor yeeb ncuab Icatibant rau kev kho mob ntawm kev ua phem heev ntawm kev muaj mob angioedema: Quick 3 preliminary. Ann Sensitivity Asthma Immunol. 2011; 107(6): 529-530.
4. Bernstein JA, Moellman J, Bernstein DI. Icatibant hauv angiotensin-hloov dua catalyst inhibitor-prompted angioedema. J Sensitivity Clin Immunol Pract. 2017;5(5):1402-1404.
5. Maurer M, Aberer W, Bouillet L, et al. Genetic angioedema assaults daws sai dua thiab muaj kev txwv ntau dua tom qab kho Icatibant thaum ntxov. PLoS Ib. 2013; 8(2):e53773.